/PRNewswire/ The clinical development of fostrox remains the focus April - June Financial summary for the quarter Net turnover amounted to SEK 0.5 (0.9).
/PRNewswire/ Medivir Aktiebolag (publ) held its annual shareholders meeting today on 5 May 2022. The annual general meeting was held by physical presence.
Resolutions at the Annual General Meeting in Medivir on 5 May 2021
News provided by
Share this article
HUDDINGE, Sweden, May 5, 2021 /PRNewswire/
Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director
The annual general meeting in Medivir Aktiebolag (publ) on 5 May 2021 resolved to approve the profit and loss accounts and balance sheets for the financial year 2020. The persons who had been board members and managing directors were discharged from liability with respect to their respective management of the company for the financial year 2020.
Appropriation of the company s profit or loss
Financing secured to bring the MIV-818 study into the next phase
January – March
Net turnover amounted to SEK 9.9 (7.3) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -7.2 (-20.7) million. Basic and diluted earnings per share amounted to SEK -0.18 (-0.96) and SEK -0.18 (-0.96) respectively.
Cash flow from operating activities amounted to SEK -1.5 (-16.6) million.
Liquid assets and short-term investments at the end of the period amounted to SEK 269.3 (116.6) million.
Significant events during the quarter
In January the company signed an exclusive license agreement with IGM Biosciences, Inc. for birinapant. Medivir received a payment of USD 1 million after signing, which is to be followed by an additional USD 1.5 million when IGM includes birinapant in phase I clinical trials. In addition, the agreement entitles Medivir to milestone payments and royalties.
Kungl. Vetenskapsakademien: New knowledge about a cancer pharmaceutical led to the Sjöberg Prize
MALMÖ, Sweden, Feb. 15, 2021 /PRNewswire/
Benjamin L. Ebert, USA, receives this year s Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals.
The story of this pharmaceutical begins with a tragedy as, in the 1950s and 1960s, pregnant women with severe morning sickness were sometimes given thalidomide. This caused a range of birth defects and the medication was removed from the market.